Krystal Morales

Krystal Morales

Auto-generated profile, based on publicly available information

Krystal Morales

Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2018 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
KMK.A. Morales
K.A. Morales
JAJulio Arevalo-Perez
Julio Arevalo-Perez
KPKyung K Peck
Kyung K Peck
AHAndrei Holodny
Andrei Holodny
ELE. Lis
E. Lis
SKS. Karimi
S. Karimi
BACKGROUND AND PURPOSE: Vertebral hemangiomas are benign vascular lesions that are almost always incidentally found in the spine. Their classic typical hyperintense appearance on T1- and T2-weighted MR images is diagnostic. Unfortunately, not all hemangiomas have the typical appearance, and they can mimic metastases on routine MR imaging. These are generally referred to as atypical hemangiomas and can result in misdiagnosis and ultimately additional imaging, biopsy, and unnecessary costs. Our objective was to assess the utility of dynamic contrast-enhanced MR imaging perfusion in distinguishing vertebral atypical hemangiomas and malignant vertebral metastases. We hypothesized that permeability and vascular density will be increased in metastases compared with atypical hemangiomas. MATERIALS AND METHODS: Consecutive patients from 2011 to 2015 with confirmed diagnoses of atypical hemangiomas and spinal metastases from breast and lung carcinomas with available dynamic contrast-enhanced MR imaging were analyzed. Time-intensity curves were qualitatively compared among the groups. Perfusion parameters, plasma volume, and permeability constant were quantified using an extended Tofts 2-compartment pharmacokinetic model. Statistical significance was tested using the Mann-Whitney U test. RESULTS: Qualitative inspection of dynamic contrast-enhanced MR imaging time-intensity curves demonstrated differences in signal intensity and morphology between metastases and atypical hemangiomas. Quantitative analysis of plasma volume and permeability constant perfusion parameters showed significantly higher values in metastatic lesions compared with atypical hemangiomas (P < .001). CONCLUSIONS: Our data demonstrate that plasma volume and permeability constant perfusion parameters and qualitative inspection of contrast-enhancement curves can be used to differentiate atypical hemangiomas from vertebral metastatic lesions. This work highlights the benefits of adding perfusion maps to conventional sequences to improve diagnostic accuracy.

15 September 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
MMMichelle L. Mierzwa
Michelle L. Mierzwa
MAMadhava Aryal
Madhava Aryal
CLChoonik Lee
Choonik Lee
MSMatthew Schipper
Matthew Schipper
MVMonica VanTil
Monica VanTil
YCYue Cao
Yue Cao
Purpose: We conducted a randomized phase II multicenter clinical trial to test the hypothesis that physiologic MRI-based radiotherapy (RT) dose escalation would improve the outcome of patients with poor prognosis head and neck cancer. Patients and Methods: MRI was acquired at baseline and at RT fraction 10 to create low blood volume/apparent diffusion coefficient maps for RT boost subvolume definition in gross tumor volume. Patients were randomized to receive 70 Gy (standard RT) or 80 Gy to the boost subvolume (RT boost) with concurrent weekly platinum. The primary endpoint was disease-free survival (DFS) with significance defined at a one-sided 0.1 level, and secondary endpoints included locoregional failure (LRF), overall survival (OS), comparison of adverse events and patient reported outcomes (PRO). Results: Among 81 randomized patients, neither the primary endpoint of DFS (HR = 0.849, P = 0.31) nor OS (HR = 1.19, P = 0.66) was significantly improved in the RT boost arm. However, the incidence of LRF was significantly improved with the addition of the RT boost (HR = 0.43, P = 0.047). Two-year estimates [90% confidence interval (CI)] of the cumulative incidence of LRF were 40% (27%–53%) in the standard RT arm and 18% (10%–31%) in the RT boost arm. Two-year estimates (90% CI) for DFS were 48% (34%–60%) in the standard RT arm and 57% (43%–69%) in the RT boost arm. There were no significant differences in toxicity or longitudinal differences seen in EORTC QLQ30/HN35 subscales between treatment arms in linear mixed-effects models. Conclusions: Physiologic MRI-based RT boost decreased LRF without a significant increase in grade 3+ toxicity or longitudinal PRO differences, but did not significantly improve DFS or OS. Additional improvements in systemic therapy are likely necessary to realize improvements in DFS and OS.

25 November 2025
Verified
Other
Open access
MMMichelle L. Mierzwa
Michelle L. Mierzwa
MAMadhava Aryal
Madhava Aryal
CLChoonik Lee
Choonik Lee
MSMatthew Schipper
Matthew Schipper
MVMonica VanTil
Monica VanTil
YCYue Cao
Yue Cao
Multi-variable model for loco-regional control in randomized patients including covariates of chemotherapy regimen and smoking history

1 April 2023
Verified
Other
Open access
MMMichelle L. Mierzwa
Michelle L. Mierzwa
MAMadhava Aryal
Madhava Aryal
CLChoonik Lee
Choonik Lee
MSMatthew Schipper
Matthew Schipper
MVMonica VanTil
Monica VanTil
YCYue Cao
Yue Cao
KM curves of average patient p16+ and p16- LRF outcomes. Plot for estimated incidence of loco-regional failure (LRF) with the median boost volume (6.9cc) and GTV primary (54.8cc) for: p16+ OPSCC (left panel) and LAHNSCC (right panel).

1 April 2023
Verified
Other
Open access
MMMichelle L. Mierzwa
Michelle L. Mierzwa
MAMadhava Aryal
Madhava Aryal
CLChoonik Lee
Choonik Lee
MSMatthew Schipper
Matthew Schipper
MVMonica VanTil
Monica VanTil
YCYue Cao
Yue Cao
Patterns of Failure in all patients enrolled to clinical trial

1 April 2023
Verified
Other
Open access
MMMichelle L. Mierzwa
Michelle L. Mierzwa
MAMadhava Aryal
Madhava Aryal
CLChoonik Lee
Choonik Lee
MSMatthew Schipper
Matthew Schipper
MVMonica VanTil
Monica VanTil
YCYue Cao
Yue Cao
Characteristics of patients in non-randomized cohort who had <1cc of overlapped LBV and LADC MRI boostable tumor subvolume.